Please use this identifier to cite or link to this item:
Title: Anti-HIV, anti-tubercular and mutagenic activities of borrelidin
Authors: Bhikshapathi, D V R N
Krishna, D R
Kishan, V
Keywords: Borrelidin;Mycobacterium tuberculosis;mutagenicity;anti-HIV reverse transcriptase enzyme
Issue Date: Jul-2010
Publisher: CSIR
Abstract: Borrelidin, an antibiotic found to be an angiogenesis inhibitor, is a potential drug candidate due to its antiangiogenic activity and other biological activities. Keeping in view the scope of the antibiotic, we have performed some of the biological activities like effect of borrelidin on Mycobacterium tuberculosis H37Rv (ATCC 27294) by BACTEC 460 TB and multidrug resistant M. tuberculosis. In these studies, the minimum inhibitory concentration (MIC) of borrelidin against M. tuberculosis H37Rv was found to be 3.12 µg/mL. When compared with known antituberculous drugs like rifampicin, isoniazid, ethambutol and streptomycin, borrelidin showed higher MIC on M. tuberculosis H37Rv (ATCC 27294). The MIC was, however, lower than that of pyrazinamide. The inhibitory activity on multidrug resistant M. tuberculosis was, observed at 256 g/mL for borrelidin, rifampicin and isoniazid. The anti-HIV reverse transcriptase activity of borrelidin was tested by ELISA test, and mutagenic effect of borrelidin was performed by Ames test. Borrelidin showed moderate activity against anti-HIV reverse transcriptase enzyme. Results of Ames test indicated that borrelidin was non-mutagenic up to 500 g/mL concentration.
Page(s): 265-270
ISSN: 0975-0967 (Online); 0972-5849 (Print)
Appears in Collections:IJBT Vol.09(3) [July 2010]

Files in This Item:
File Description SizeFormat 
IJBT 9(3) 265-270.pdf233.95 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.